Skip to main navigation menu Skip to main content Skip to site footer

Review article: Biomedical intelligence

Vol. 141 No. 4950 (2011)

Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma

  • R Dummer
  • M Guggenheim
  • AW Arnold
  • R Braun
Cite this as:
Swiss Med Wkly. 2011;141:w13320


Melanoma is the most common lethal cutaneous neoplasm. In order to harmonise treatment and follow-up of melanoma patients, guidelines for the management of melanoma in Switzerland were inaugurated in 2001 and revised in 2006. A new classification and recent results in randomised trials necessitated changes concerning staging and modifications of the recommendations of therapy and follow-up.


  1. Dummer R, Bosch U, Panizzon R, Bloch PH, Burg G. Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology. 2001;203:75–80.
  2. Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G. Melanoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v194–197.
  3. Dummer R, Panizzon R, Bloch PH, Burg G. Updated swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology. 2005;210:39–44.
  4. Bono A, Tolomio E, Trincone S, Bartoli C, Tomatis S, Carbone A, Santinami M. Micro-melanoma detection: A clinical study on 206 consecutive cases of pigmented skin lesions with a diameter < or = 3 mm. Br J Dermatol. 2006;155:570–3.
  5. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 ajcc melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.
  6. Garbe C, Eigentler TK, Bauer J, Blodorn-Schlicht N, Fend F, Hantschke M, et al. Histopathological diagnostics of malignant melanoma in accordance with the recent ajcc classification 2009: Review of the literature and recommendations for general practice. J Dtsch Dermatol Ges. 2011.
  7. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using grenz or soft x-rays. Br J Dermatol. 2002;146:1042–6.
  8. Balch CM, Morton DL, Gershenwald JE, McMasters KM, Nieweg OE, Powell B, et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009;60:872–5.
  9. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46:270–83.
  10. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage iii melanoma: Final results of eortc 18991, a randomised phase iii trial. Lancet. 2008;372:117–26.
  11. Santillan AA, Messina JL, Marzban SS, Crespo G, Sondak VK, Zager JS. Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: Impact on treatment decisions. J Clin Oncol. 2010;28:481–6.
  12. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.
  13. Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse CW, et al. The augsburg consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer. 2000;89:236–41.
  14. Guggenheim MM, Hug U, Jung FJ, Rousson V, Aust MC, Calcagni M, et al. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. Ann Surg. 2008;247:687–93.
  15. Leiter U, Buettner PG, Bohnenberger K, Eigentler T, Meier F, Moehrle M, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol. 2010;17:129–37.
  16. Guggenheim M, Dummer R, Jung FJ, Mihic-Probst D, Steinert H, Rousson V, et al. The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma – a retrospective analysis of 392 cases. Br J Cancer. 2008;98:1922–8.
  17. Scolyer RA, Murali R, Gershenwald JE, Cochran AJ, Thompson JF. Clinical relevance of melanoma micrometastases in sentinel nodes: Too early to tell. Ann Oncol. 2007;18:806–8.
  18. Cascinelli N, Bombardieri E, Bufalino R, Camerini T, Carbone A, Clemente C, et al. Sentinel and nonsentinel node status in stage ib and ii melanoma patients: Two-step prognostic indicators of survival. J Clin Oncol. 2006;24:4464–71.
  19. Satzger I, Volker B, Meier A, Schenck F, Kapp A, Gutzmer R. Prognostic significance of isolated hmb45 or melan a positive cells in melanoma sentinel lymph nodes. Am J Surg Pathol. 2007;31:1175–80.
  20. van Akkooi AC, Nowecki ZI, Voit C, Schafer-Hesterberg G, Michej W, de Wilt JH, et al. Sentinel node tumor burden according to the rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes. Ann Surg. 2008;248:949–55.
  21. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the john wayne cancer clinic. Ann Surg. 1991;214:491–9; discussion 499–501.
  22. Kleeberg UR, Suciu S, Broecker EB, Ruiter DJ, Chartier C, Liénard D, et al., (DKG) ftEMGicwtGCS: Final results of the eortc 18871/dkg 80-1 randomised phase iii trial: Rifn-alpha 2b versus rifn-gamma versus iscador m versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer. 2004;40:390–402.
  23. McLoughlin JM, Zager JS, Sondak VK, Berk LB. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control. 2008;15:239–47.
  24. Overgaard J. Radiation treatment of malignant melanoma. Int J Radiat Oncol Biol Phys. 1980;6:41–4.
  25. Konefal JB, Emami B, Pilepich MV. Malignant melanoma: Analysis of dose fractionation in radiation therapy. Radiology. 1987;164:607–10.
  26. Overgaard J, Overgaard M, Hansen PV, von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol. 1986;5:183–92.
  27. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase iii study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–66.
  28. Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazinie in stage iv malignant melnaoma: Final results of the randomised phase iii study (eortc 18032). Ann Oncol. 2008:19 Abstr LBA18.
  29. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (cvd) for metastatic melanoma. Cancer. 1989;64:2024–9.
  30. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase iii, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage iii or stage iv melanoma. J Clin Oncol. 2009;27:2823–30.
  31. Hamm C, Verma S, Petrella T, Bak K, Charette M. Biochemotherapy for the treatment of metastatic malignant melanoma: A systematic review. Cancer Treat Rev. 2008;34:145–56.
  32. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol. 2007;25:5426–34.
  33. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
  34. Robert C, Thomas L, Bondarenko I, O’Day S, M DJ, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.
  35. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with braf v600e mutation. N Engl J Med. 2011;364:2507–16.
  36. O'Day S, Kim JA, Sosman AC, Petersion S, Feng DR, Minor JP, et al. A randomized phase ii study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untrated advanced melanoma. Eur J Cancer Supp. 2009;7:Abstract 23LBA.
  37. von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, et al. First-line temozolomide combined with bevacizumab in metastatic melanoma: A multicenter phase ii trial (sakk 50/07). Ann Oncol. 2011.
  38. Titus-Ernstoff L, Perry AE, Spencer SK, Gibson J, Ding J, Cole B, et al. Multiple primary melanoma: Two-year results from a population-based study. Arch Dermatol. 2006;142:433–8.
  39. Saiag P, Bosquet L, Guillot B, Verola O, Avril MF, Bailly C, et al. Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the french standards, options and recommendations guidelines. Summary report. Eur J Dermatol. 2007;17:325–31.
  40. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. The lancet oncology. 2005;6:608–21.
  41. Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, et al. Short german guidelines: Malignant melanoma. J Dtsch Dermatol Ges. 2008;6(Suppl 1):S9–S14.
  42. Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, et al. Prospective comparison of [18f]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: Diagnostic accuracy and impact on treatment. J Clin Oncol. 2009;27:4774–80.
  43. Beyeler M, Waldispuhl S, Strobel K, Joller-Jemelka HI, Burg G, Dummer R. Detection of melanoma relapse: First comparative analysis on imaging techniques versus s100 protein. Dermatology. 2006;213:187–91.
  44. Kruijff S, Bastiaannet E, Muller Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ. Erratum to: S-100b concentrations predict disease-free survival in stage iii melanoma patients. Ann Surg Oncol. 2010.